Explainable artificial intelligence for cough-related quality of life impairment prediction in asthmatic patients

Sara Narteni^{1,2,*}, Ilaria Baiardini³, Fulvio Braido³, Maurizio Mongelli¹

1 CNR-IEIIT, Corso F.M. Perrone 24, 16152, Genoa, Italy 2 Politecnico di Torino, DAUIN Department, Corso Duca degli Abruzzi 24, 10129, Turin, Italy 3 IRCCS Policlinic Hospital San Martino, Respiratory Diseases and Allergy Department, Genoa, Italy

* sara.narteni@ieiit.cnr.it

Abstract

Explainable Artificial Intelligence (XAI) is becoming a disruptive trend in healthcare, allowing for transparency and interpretability of autonomous decision-making. In this study, we present an innovative application of a rule-based classification model to identify the main causes of chronic cough-related quality of life (QoL) impairment in a cohort of asthmatic patients. The proposed approach first involves the design of a suitable symptoms questionnaire and the subsequent analyses via XAI. Specifically, feature ranking, derived from statistically validated decision rules, helped in automatically identifying the main factors influencing an impaired QoL: pharynx/larynx and upper airways when asthma is under control, and asthma itself and digestive trait when asthma is not controlled. Moreover, the obtained *if-then* rules identified specific thresholds on the symptoms associated to the impaired QoL. These results, by finding priorities among symptoms, may prove helpful in supporting physicians in the choice of the most adequate diagnostic/therapeutic plan.

Introduction the contraction of the contraction of

Nowadays Artificial Intelligence (AI) is revolutionizing medicine by leveraging powerful ² technologies and advanced learning algorithms. This has the potential to support ³ several clinical processes, from prognostics to diagnostics, from treatment management ⁴ to drug discovery, and also can aid hospital administrative tasks. However, AI real application in healthcare needs to be approached very carefully, since failures may cause harm to human lives. For this reason, AI research is increasing its interests in trustworthy AI [\[1\]](#page-9-0), a broad paradigm establishing how to properly design, develop and deploy real-world AI applications. Between its principles, *transparency* requires providing the user with an understanding of the autonomous decisions generated by the ¹⁰ model: this topic is subject of eXplainable AI (XAI) research [\[2,](#page-9-1)3]. XAI comprehends a $_{11}$ wide range of methodologies, which can be broadly categorized as post-hoc explanations 12 of black box models and transparent-by-design techniques [\[4\]](#page-9-3). In the latter category, ¹³ rule-based models are characterized by understandable decision rules expressed in the ¹⁴ if -then format. These kinds of models are particularly suitable in medicine, since their $\frac{1}{15}$ intrinsic interpretability allows clinicians to enter models' logic and increase trust in $\frac{16}{16}$ them. In light of this, our work focuses on the usage of such techniques to characterize $\frac{1}{12}$ the quality of life of asthmatic patients with chronic cough. 18

> Asthma is a frequent cause of cough in adults [\[5\]](#page-9-4). In addition to coughing, asthmatic ¹⁹ patients may also wheeze or feel short of breath. However, some people have a condition $_{20}$ known as cough variant asthma, in which cough is the only symptom of asthma. For $\frac{21}{21}$ these reasons, tools for the assessment of asthma, such as Asthma Control Test 22 (ACT) [\[19\]](#page-10-0), consider cough among the asthma features. While in patients with ²³ uncontrolled asthma the disease itself can be the cause of cough, the persistence of $_{24}$ cough despite good asthma control can be related to concomitant disorders (i.e., ²⁵ postnasal drip, pharynx/larynx disorders, and acid reflux from the stomach [\[6\]](#page-9-5)) or ²⁶ inability of asthma drugs to fully remove the symptoms. $\frac{27}{27}$

> In light of these considerations, it is very useful to design a method that allows to $\frac{28}{28}$ define the priority of choice among different diagnostic techniques, starting from ²⁹ patients' self-reported presence and entity of symptoms and their impact on the quality $\frac{30}{20}$ of life. Methods based on XAI, thanks to their transparent and interpretable methods, ³¹ can offer a great opportunity in this direction. $\frac{32}{2}$

Contribution 33

In this study, we propose the usage of a rule-based XAI model to support clinicians in $\frac{34}{4}$ the diagnostic procedure for determining the origins of chronic cough in asthmatic ³⁵ patients. More precisely, our main contributions are the following:

- We introduce a new block-based questionnaire, devoted to collect (respiratory) 37 symptoms perceived by asthmatic patients with chronic cough. $\frac{38}{100}$
- We train a rule-based model, the Logic Learning Machine (LLM), for predicting $\frac{39}{2}$ chronic cough-related quality of life based only on self-reported responses to the ⁴⁰ questionnaire of symptoms, by distinguishing patients with high or low asthma 41 control level. $\frac{42}{42}$
- By validating and analyzing the model, we discover which symptoms and \bullet corresponding values are mainly involved in a quality of life exacerbation. ⁴⁴

The remaining part of the paper is organized as follows. In Section [Related Work](#page-1-0) we ⁴⁵ report some recent examples of machine learning for chronic cough. Section ⁴⁶ [Methodology](#page-2-0) describes the workflow, the dataset structure and the adopted 47 methodologies. Section [Results](#page-5-0) shows and discusses the obtained results. Finally, ⁴⁸ Section [Conclusion](#page-8-0) concludes the paper and reports future research on the topic. ⁴⁹

Related Work ⁵⁰

Different machine learning (ML) and AI-based studies on chronic cough and asthma have been carried out in recent years, by leveraging the newest medical technologies [\[17\]](#page-10-1). $\frac{52}{2}$ An AI-based cough count, CoughyTM [\[14\]](#page-10-2), system was recently developed that $\frac{53}{14}$ quantifies cough sounds collected through a smartphone application. Study results $\frac{54}{10}$ showed that suggest that CoughyTM could be a novel solution for objectively 55 monitoring cough in a clinical setting. A vocal biomarker-based machine learning 56 approaches have shown promising results in the detection of various health conditions, $\frac{57}{2}$ including respiratory diseases, such as asthma [\[15\]](#page-10-3). Also, a deep learning model for identifying chronic cough patients with even higher sensitivity and specificity when $\frac{59}{2}$ structured and unstructured electronic health records EHR data are utilized has been 60 proposed $[16]$.

In $[12]$, well established ML models like gradient boost and random forest were $\frac{62}{2}$ adopted in a retrospective study to predict the risk of persistent chronic cough (PCC) \qquad 63 in patients with chronic cough (CC) . The work proposed in [\[7\]](#page-9-6) used a statistical $\frac{64}{64}$

> approach (Latent Class Analysis) on the Swedish Twin study On Prediction and ⁶⁵ Prevention of Asthma (STOPPA) and the Child and Adolescent Twin Study in Sweden 66 (CATSS) questionnaires responses to identify asthma and wheeze phenotypes in $\frac{67}{67}$ children. In $[9]$, four adult chronic cough phenotypes were identified through a cluster analysis method applied to questionnaire data such as the COugh Assessment Test ⁶⁹ $(COAT)$ [\[10\]](#page-9-8) and the Korean version of the Leicester Cough Questionnaire [\[11\]](#page-9-9).

> However, all these literature examples do not provide their outcomes in an $_{71}$ explainable way. The set of the set

 $\mathbf{Methodology}$ and the set of \mathbb{Z}_2 and \mathbb{Z}_3

$\mathbf{Workflow}$ $\qquad \qquad$

The overall methodology followed in the proposed analyses is depicted in Fig. [1.](#page-2-1) The

Fig 1. Workflow of the analyses carried out in the proposed XAI-based approach.

dataset was first split in a 70% training and 30% test sets, then an explainable Artificial τ_6 Intelligence (XAI) model was considered for data classification. The adopted classifier is π called Logic Learning Machine and provides its predictions through a set of rules. In $\frac{1}{78}$ order to verify the statistical significance of the resulting ruleset, this was validated $\frac{79}{20}$ through a statistical test. Rules that did not pass the test were then filtered out from \bullet the model, thus obtaining a final, validated, set of rules. Also, feature ranking was investigated to identify which of the inputs have the higher impact on the model $\frac{82}{2}$ outcome. Finally, the overall performance of the validated ruleset was measured on the ⁸³ test set, by considering some common metrics for machine learning models evaluation. $\frac{1}{84}$

Next Sections provide the description of the dataset and some fundamentals about ⁸⁵ the adopted XAI, the rule validation test and the definition of the evaluation metrics. \bullet

Dataset Description and the state of the

The study involved a cohort of asthmatic patients, who have been asked to answer to $\frac{88}{88}$ three different kinds of questionnaires (data were accessed on $2023/03/08$; the authors $\frac{89}{90}$ had no access to information that could allow to identify individual participants during $\frac{90}{2}$ or after data collection). $\frac{91}{2}$

The first one collects patients' feedback about a variety of symptoms. Specifically, it $\frac{92}{2}$ contains 19 items relating to four domains related to the more frequent causes of $\frac{93}{2}$ chronic cough, as shown in the diagram of Fig. [2.](#page-2-2)

Fig 2. Symptoms questionnaire. Schematic representation of the four blocks $(AsthmaRelated, PharynxLarynx, Rhino Sinusitis, GastroEsoReflux)$ of the symptoms questionnaire and their related items.

For each item, the patients answered to the question "How intense/annoying has the 95 symptom been in the last month?", by self-reporting a level between None and Very $\frac{1}{2}$ *Much* expressing the perceived entity of the corresponding symptom. These levels were $\frac{97}{20}$ then proportionally converted to a score in the $0-100$ scale. The average of the responses $\frac{98}{98}$ within each block was computed, thus individuating a set of four features that will be ⁹⁹ used as input to the ML model, each referred to a different body organ.

The second questionnaire involved in this study is the Chronic Cough Impact 101 Questionnaire (CCIQ) [\[18\]](#page-10-6). It is useful to measure the impact of cough on health-related $_{102}$

75

> quality of life, namely *impact on daily life (CCIQ IDL)*, on sleep/concentration (CCIQ $_{103}$ SC), on mood (CCIQ M) and relationship (CCIQ R). A score for each group is derived $_{104}$ and contributes to compute a global score, called CCIQ GLS : based on this, we defined $_{105}$ two classes of patients. Those scoring $CCIQ$ $GLS \geq 20$ were labelled as *impaired Quality* 106 of Life (QoL), while those with CCIQ GLS < 20 were associated to a near normal QoL. $_{107}$

> The last questionnaire considered is the Asthma Control Test (ACT) [\[19\]](#page-10-0). It is a 108 5-item questionnaire aimed at assessing at which extent the asthmatic patient has ¹⁰⁹ control of the pathology. We used the score obtained from this test to further 110 distinguish patients between two populations: subjects with $ACT \geq 20$ were identified $\frac{1}{111}$ as the *controlled asthma* group, whereas those scoring $ACT < 20$ formed the not $controlled \; asthma \; group.$

> The analyses carried out in this work thus considered three different cases: i) all patients were included; ii) only *controlled* asthma patients were included; iii) only not 115 controlled asthma patients were included.

The Adopted eXplainable AI classifier 117

For each patients group, we trained a XAI classifier that, fed with the 4 input features 118 (referred to as AsthmaRelated, PharynxLarynx, RhinoSinusitis and $GastroEsoReflux$) 119 representing the average scores on each block of the symptoms questionnaire (Fig. [2\)](#page-2-2), $_{120}$ provided a prediction of the patient's cough-related QoL, which can be either *impaired* 121 or near normal.

The analyses on the first group (i.e., all patients) did not explicitly use the knowledge $_{123}$ acquired from the ACT questionnaire. Indeed, the classification model that is designed $_{124}$ for this group represents a tool to individuate which areas and values of symptoms drive 125 an impaired QoL in a generic asthmatic population, but without any previous 126 knowledge on the asthma control level. Conversely, the analyses performed on the 127 controlled asthma and not controlled asthma groups also exploited the information from 128 the ACT, thus the results of the XAI predictive models provide indications that are $_{129}$ specifically tailored to the different asthma control level.

Logic Learning Machine 131

In this Section, we provide some basic description of the adopted classifier, the Logic $_{132}$ Learning Machine (LLM). It is a rule-based explainable AI model, designed and 133 developed by Rulex [\[26\]](#page-11-1) as the efficient implementation of Switching Neural ¹³⁴ $Networks [20].$ $Networks [20].$ $Networks [20].$

Given the input data, the LLM provides a classification model described by a set of $\frac{136}{2}$ rules $\mathcal{R} = \{r_k\}_{k=1,\dots,N_r}$, where each r_k is expressed with the form: if \leq premise $>$ then 137 $\langle consequence \rangle$. The $\langle premise \rangle$ constitutes the antecedent of the rule and is a logical 138 conjunction (AND) of conditions on the input features. The $\langle\text{consequence}\rangle$ reports the 139 outcome of the classification, i.e. the predicted class label. ¹⁴⁰

The performance of any rule $r_k \in \mathcal{R}$ can be evaluated by covering $C(r_k)$ and error 141 $E(r_k)$ metrics, defined as: 142

$$
C(r_k) = \frac{TP(r_k)}{TP(r_k) + FN(r_k)}\tag{1}
$$

$$
E(r_k) = \frac{FP(r_k)}{TN(r_k) + FP(r_k)}
$$
\n(2)

where $TP(r_k)$ and $FP(r_k)$ are the number of samples that, respectively, correctly and 144 wrongly verify rule r_k ; $TN(r_k)$ and $FN(r_k)$ are the number of samples that, respectively, correctly and wrongly do *not* verify the rule. The covering is also 146

> proportional to the relevance of the rule, therefore the larger it is, the higher is the $_{147}$ probability that the rule is valid on new unseen samples. On the contrary, the error ¹⁴⁸ $E(r_k)$ measures how much wrongly covered is the rule and its maximum value is usually $_{149}$ fixed as a model hyperparameter (by default, it is of 5%).

> Both covering and error are useful to define *feature ranking*. It allows to gain insights on 151 which input attributes contribute the most to predict a given class; to this aim, values 152 of relevance for each feature are computed and typically represented in bar plots in ¹⁵³ descending order.

> Given a feature X_i and a rule r_k (predicting class label \hat{y}) containing in its premise a 155 condition c_j on variable X_j , covering and error are first combined to compute the 156 relevance of c_j as $R(c_j) = (E(r'_k) - E(r_k))C(r_k)$, where r'_k is the rule obtained by removing condition c_j from r_k . The relevance $R_j^{\hat{y}}$ for feature X_j is then derived by the 158 following equation [3:](#page-4-0) 159

$$
R_j^{\hat{y}} = 1 - \prod_k \left(1 - R\left(c_j\right)\right),\tag{3}
$$

where the product is computed on the rules r_k that include a condition c_j on the 160 feature of interest. ¹⁶¹

$\mathbf{Rules~Statistical~Validation}$ 162

In order to assess the statistical significance of the set of rules generated by the LLM, $_{163}$ we decided to use the Pearson's χ^2 independence test [\[23\]](#page-11-2). To this purpose, we considered two binary events involving the available data samples, namely their ¹⁶⁵ membership to an output class and their satisfaction of the rules in \mathcal{R} . Therefore, a 2×2 166 contingency table was built for each rule $r_k \in \mathcal{R}$, as shown in Table [1,](#page-4-1) reporting the 167 counts of how many samples of the two classes are covered or not by the rule. ¹⁶⁸

Let the input dataset be $\mathcal{T} = \{(\mathbf{x}_i, y_i)\}_{i=1,\dots,N}$, with binary output labels $y_i = 0$ 169 (i.e., near normal QoL class in our case) or $y_i = 1$ (i.e., *impaired* QoL class). Also, let us τ_{10} define with $\mathbf{x}_i \vdash r_k$ and $\mathbf{x}_i \nvdash r_k$ the satisfaction and unsatisfaction of rule r_k by the data 171 point \mathbf{x}_i , respectively. Then, the following quantities can be defined: \mathbf{x}_i

$$
a = |\{(\mathbf{x}_i, y_i) \in \mathcal{T} | y_i = 1 \land \mathbf{x}_i \vdash r_k \}|
$$

\n
$$
b = |\{(\mathbf{x}_i, y_i) \in \mathcal{T} | y_i = 1 \land \mathbf{x}_i \nvdash r_k \}|
$$

\n
$$
c = |\{(\mathbf{x}_i, y_i) \in \mathcal{T} | y_i = 0 \land \mathbf{x}_i \vdash r_k \}|
$$

\n
$$
d = |\{(\mathbf{x}_i, y_i) \in \mathcal{T} | y_i = 0 \land \mathbf{x}_i \nvdash r_k \}|
$$

Table 1. 2×2 contingency matrix for rule r_k .

 χ^2 statistic was then computed starting from the matrix. The test was carried out 173 with a null hypothesis of independence between class label and rule membership, with a $_{174}$ significance level of 0.05 for the p-value. Rules with a p-value < 0.05 were then proved 175 as statistically significant $[24]$ and those that did not pass the test were removed from 176 the ruleset R, giving rise to a set of validated rules $\mathcal{R}_{val} \subseteq \mathcal{R}$. 177

$\bf{Model\; Performance\; Evaluation} \tag{178}$

To evaluate the overall performance of the validated ruleset, the confusion matrix ¹⁷⁹ reporting the True Positives (TP, i.e., patients correctly predicted as *impaired* QoL *)*, \quad False Positives (FP, i.e., near normal QoL patients wrongly predicted as *impaired* QoL), 181 True Negatives (TN, i.e., patients correctly predicted as *near normal* QoL *)* and False $_{182}$ Negatives (FN, i.e., *impaired QoL* patients wrongly predicted as *near normal QoL*) $\frac{1}{183}$ obtained by applying such rules to a test set was first built. It is the basis to define the ¹⁸⁴ following measurements, particularly useful when evaluating the outcomes of a clinical 185 $\text{ML model } [25]:$ $\text{ML model } [25]:$ $\text{ML model } [25]:$

$$
ACC = \frac{TP + TN}{TP + FP + TN + FN} \qquad F_1 = \frac{2TP}{2TP + FP + FN}
$$
\n
$$
PPV = \frac{TP}{TP + FP} \qquad NPV = \frac{TN}{TN + FN}
$$
\n
$$
TPR = \frac{TP}{TP + FN} \qquad TNR = \frac{TN}{TN + FP}
$$

While accuracy (ACC) and F_1 -score (F₁) provide an evaluation of the model taking into 187 account its performance on both the classes, the other ones assess the performance on 188 single classes. In detail, Positive Predictive Value (or precision, PPV) and True Positive ¹⁸⁹ Rate (or sensitivity or recall, TPR) reflect the number of TPs over the total amount of $_{190}$ positive predictions and the total amount of positive samples, respectively. Viceversa, ¹⁹¹ Negative Predictive Value (NPV) and True Negative Rate (or specificity, TNR) ¹⁹² represent the number of TNs over the total amount of negative predictions and the total ¹⁹³ quantity of negative samples, respectively.

 Results

This study involved a population of 283 asthmatic patients (i.e., the all group), with $_{196}$ age 33.5 ± 7.77 and characterized by a Forced Expiratory Volume in the first second $_{197}$ (FEV1) of $96.5\% \pm 19.09$ and an ACT score of 19.09 ± 4.98 . 146 patients belong to the 198 *controlled asthma* group (i.e., the 52% of the whole population), while the remaining 137 m patients form the *not controlled asthma* group. 200

Data statistics at a first glance 201

Figure [3](#page-5-1) provides a first glance on how the four blocks of symptoms are distributed $_{202}$ between the two classes (impaired QoL and near normal QoL) both in the controlled ²⁰³ and not controlled asthma patients. Each colored bar individuates a different group of ²⁰⁴ patients and its length (the interquartile range, or IQR) varies between the 25th and ²⁰⁵ 75th percentiles, while the vertical dashed lines (i.e., the whiskers) range from the ²⁰⁶ minimum to the maximum values and, finally, the horizontal dot-dashed black line 207 points out the median value of the corresponding symptoms group. The red $+$ markers \sim 208 represent outlier points. It is possible to observe that *PharynxLarynx* can better

Fig 3. Box plots. Graphs showing the class distributions in the controlled versus not controlled patients groups, for each of the considered features.

distinguish the two classes in the controlled asthma group, since the median value of \qquad 210 one class falls outside the bar of the other. A similar reasoning holds for the not ²¹¹ controlled asthma group, where AsthmaRelated, PharynxLarynx and GastroEsoReflux $_{212}$ stand out. However, this kind of evaluation is based on visual analytics and simple $_{213}$

> statistics, and the results do not provide any guarantee of validity on new, unseen, patients. This is why we decided to rely on machine learning-based approaches. ²¹⁵

Explainable AI-based analysis ²¹⁶

For each of the considered cases, the LLM algorithm was trained on a 70% training set $_{217}$ and generated a set of rules. In particular, for the *all* group, 19 rules were generated (8 m/s) predicting *impaired QoL* class and 11 the *near normal QoL*); from the *controlled asthma* $_{219}$ case, we got 13 rules (4 for the *impaired QoL* and 9 for the *near normal QoL* class); $_{220}$ lastly, 9 rules derived from the *not controlled asthma* group (5 referring to the *impaired* $_{221}$ QoL and 4 to the *near normal QoL* class). 222

The Pearson's χ^2 validation test was then carried out to statistically proof the 223 obtained rulesets, as per the procedure detailed in Section . After the test, 2 rules out ²²⁴ of 8 for the *impaired QoL* class and 4 out of 11 for the *near normal QoL* class were $_{225}$ validated in the *all* case; 2 of the 4 rules predicting the *impaired QoL* class in the $_{226}$ $controlled$ *asthma* group resulted significant, while 3 out of 9 rules for the other class $_{227}$ was validated in the same group; similarly, in the *not controlled asthma* patients, 2 rules 228 out of 5 for the *impaired QoL* class passed the test, while 3 out of 4 rules related to the $_{229}$ $near\ normal\ QoL\ \mathrm{did.}$

Model performance metrics $\frac{231}{231}$

After validating the rules, we thus have been able to define a final set of rules for each 232 case, by leaving out from the original rulesets all those which tested not significant. The ²³³ predictive performance of the validated rulesets was assessed on the test set, by ²³⁴ computing the metrics described in Sec. ; their values are depicted and compared in Fig. ²³⁵ [4](#page-6-0) for the three groups.

Fig 4. Validated rules performance. Percentage values of the accuracy (ACC), F1-score (F1), Positive Predictive Value (PPV), Negative Predictive Value (NPV), True Positive Rate (TPR) and True Negative Rate (TNR) of the LLM in the three patients' groups.

The accuracy reached at least 70% in all cases, thus showing good performance of 237 the validated rulesets. While also F_1 score value was high for the all and not controlled 238 asthma groups (75% and 83%, respectively), it was lower (57%) for the *controlled* $_{239}$ asthma group, denoting both poorer precision and recall. Indeed, PPV and TPR $_{240}$ metrics, related to the positive class (i.e., impaired QoL), were found 66% and 50% , $_{241}$ respectively, whereas NPV and TNR (reflecting the model's performance on the $_{242}$ negative class, i.e., the near normal QoL) were sensitively larger (74\% and 85\%), respectively). In contrast, the *not controlled asthma* reached a high F_1 due to larger \qquad values of precision and recall, with a PPV of 77% and TPR of 89%; on the other hand, ²⁴⁵ NPV and TNR resulted in lower values. A similar reasoning holds for the all group, $_{246}$ even if the model performance on the two classes was more balanced, with less $_{247}$ difference among the metrics for the positive and the negative class.

Most relevant symptoms questionnaire items ²⁴⁹

Further insights on the LLM results were obtained by visualizing the feature ranking. 250 Bar plots, obtained for the three cases under analysis, are shown in Fig. [5,](#page-7-0) representing 251 the *impaired QoL* class feature ranking, that highlights which of the features influenced $_{252}$ more the LLM decision towards that class. Concerning the *all* group, from Fig. $5A$ 253 AsthmaRelated and PharynxLarynx were individuated as the main factors leading to an $_{254}$

> Fig 5. Feature Ranking. LLM feature ranking for the impaired QoL class in the three cases. (A): all group; (B): controlled asthma group; (C): Not controlled asthma group.

impaired cough-related quality of life. In contrast, the main attributes for the *controlled* 255 asthma group (Fig.5B) were *PharynxLarynx* and *RhinoSinusitis*. Finally, dominant $\frac{256}{2}$ features for the not controlled asthma resulted AsthmaRelated and GastroEsoReflux 257 $(Fig. 5C)$.

The presence of AsthmaRelated as a relevant factor for the not controlled asthma group is in line with our expectation, since the deterioration of these patients' QoL ²⁶⁰ reasonably depends on the asthma itself and the clinical investigation should be ²⁶¹ primarily addressed to it. Secondarily, the digestive tract should be considered. Conversely, the feature ranking for the *controlled asthma* patients provides the 263 indication that further clinical assessments should focus first on the throat and, then, on ²⁶⁴ the nose. By using the symptoms questionnaire, in absence of any information about ₂₆₅ the patient's asthma control level, results suggest to first consider the asthma and then ²⁶⁶ the nose. 267

Symptoms questionnaire scores driving impaired QoL ²⁶⁸

While previous Section provided which are the main factors involved in the impaired $_{269}$ QoL, in this Section our focus is posed on the information we can derive by inspecting ²⁷⁰ the validated rules predicting the *impaired QoL* class, which are reported in Table [2.](#page-7-1) $_{271}$ Their aim is to define useful criteria to support clinicians in the diagnostic process, by

Table 2. Criteria for *impaired QoL* prediction through symptoms questionnaire, as emerged from LLM rules validated through the χ^2 independence test, for each considered patient group. Pink-colored cells highlight the rules that were proved the most performing even on previously unseen patients.

Case	Significant Rules	Covering $(\%)$	Error $(\%)$
All	1. if AsthmaRelated > 8.16 and PharynxLarynx > 15.12 and RhinoSinusitis ≤ 70.43 and GastroEsoReflux > 8.62 then <i>impaired QoL</i>	57	4.1
	2. if AsthmaRelated > 28.16 and 7.93 \lt RhinoSinusitis \lt 70.43 and GastroEsoReflux > 4.62 then <i>impaired QoL</i>	56.	4.1
Controlled Asthma	1. if AsthmaRelated > 10.83 and PharynxLarynx > 23.46 and RhinoSinusitis ≤ 69.81 then <i>impaired QoL</i>	47	3.7
	2. if PharynxLarynx \leq 13.25 and 11.57 \leq RhinoSinusitis \leq 26.78 and GastroEsoReflux > 0.62 then impaired QoL	21	3.7
Not controlled Asthma	1. if AsthmaRelated > 50.83 and RhinoSinusitis \leq 70.43 then <i>impaired QoL</i>	52	0.0
	2. if GastroEsoReflux > 28.375 then <i>impaired QoL</i>	41	0.0

individuating, in the three cases, which values assumed by the symptoms questionnaire $\frac{273}{273}$ scores are more probably associated to an *impaired QoL* status. However, by looking at $_{274}$ the threshold values of a same indicator in the two rules for a given group, it can be $_{275}$ noticed that they can be pretty different or even conflicting. For example, the 8.16 and 276 the 28.16 in the AsthmaRelated score for the all group have a difference of 20 277 percentage points, which cannot be disregarded; also, the condition on *PharynxLarynx* $_{278}$ in the *controlled asthma* group is discordant in the two related rules, the first stating $_{279}$ that values larger than 23.46 lead to QoL deterioration, while the second states the ²⁸⁰ same for values lower than 13.25. Regarding the *not controlled asthma* case, the two $_{281}$ rules seem to individuate two clusters of patients, one depending on increasing $(5.50.83)$ 282 AsthmaRelated score and decreasing (≤ 70.43) RhinoSinusitis score, and the other 283 depending on $GastroEsoReflux$ score only. Therefore, rule generation alone is able to $_{284}$ individuate several clusters of patients, each described by a pretty different set of $\frac{285}{285}$

> conditions on the questionnaire scores. Nevertheless, our final goal is to provide, ²⁸⁶ through the ML system, more general information to be used in clinical practice, $_{287}$ especially valid in the case of new, never seen before, patients.

> Further evaluations of the models are then carried out for a better knowledge extraction suitable to our objective. Covering and error percentages reported in the ²⁹⁰ Table have been derived during model training on the training data portion. Hence, their values, even when considerably high (as in the cases of $>50\%$ covering), do not $_{292}$ guarantee the same performance on test (previously unseen) data. Thus, percentages of ²⁹³ impaired QoL test points satisfying either one, both or even none of the two rules were ²⁹⁴ computed to understand how the original covering changes on new data; the obtained 295 values are outlined in Table [3.](#page-8-1) When points satisfy both rules, the most important one

Table 3. Satisfaction percentages of validated rules for the *impaired QoL* class on unseen data. For each group, Rule 1 refers to rule number 1 of Table [2,](#page-7-1) and, similarly, Rule 2 here refers to rule number 2.

	Rule 1		Rule 2 Both rules No rules	
Δ ll	20.41%	14.28\%	44.90%	20.41%
Controlled asthma	41.67\%	8.33\%	0%	50%
Not controlled asthma	37.04%	37.04\%	14.81\%	11.11%

can still be individuated as the highest-covering one (from Tab. [2\)](#page-7-1). Thus, the 44.90% 297 rate of satisfaction of both rules in the all group contributes to the rate of rule 1 (of the 298 same group), which then reaches a total value of 65.31% of satisfaction. Thus, this rule 299 should be taken as a reference for individuating the factors with higher impact on the $\frac{3000}{2000}$ impaired QoL. The same reasoning holds for the *not controlled asthma* group, where $\frac{301}{200}$ rule 1 reaches the about the 52% . Regarding the *controlled asthma* case, rule 1 proves as the most frequently validated by the unseen patients. Moreover, it is worth noting 303 that the sum of the percentages shown in Table for Rule 1, Rule 2 and Both rules $_{304}$ columns corresponds to the TPR computed in Fig. [4.](#page-6-0) Hence, in this analysis we can see $\frac{305}{200}$ the specific contribution of the two rules in determining its value. $_{306}$

In summary, for each of the three groups, a rule has emerged as the one with the $\frac{307}{207}$ best predictive ability for an *impaired QoL* status and it can be considered as a helpful $\frac{308}{200}$ decision-making support for clinicians, especially at the beginning of the clinical ³⁰⁹ evaluation process. Indeed, by using the information from the feature ranking (Fig. [5\)](#page-7-0), ³¹⁰ we discovered the main blocks of symptoms associated to an impaired QoL status due $\frac{311}{200}$ to chronic cough and the individuated decision rules define which ranges of values $\frac{312}{2}$ should be considered alarming on those variables. $\frac{313}{2}$

 $\mathbf{Conclusion}$ $\qquad \qquad \text{314}$

In this work, we proposed the evaluation of the quality of life of asthmatic patients, $\frac{315}{2}$ with lower or higher degree of asthma control, experiencing chronic cough. To this end, $\frac{316}{2}$ we first developed a questionnaire to collect patients' symptoms in relation to the most $\frac{317}{217}$ frequent causes of chronic cough (i.e., upper airways, pharynx/larynx, digestive tract, ³¹⁸ lower airways). The LLM-based analysis of patients' responses to the questionnaire $\frac{319}{2}$ items, through feature ranking, helped in automatically identifying priorities among ³²⁰ these causes: pharynx/larynx and upper airways when asthma is sufficiently controlled, $\frac{321}{2}$ and asthma itself and digestive trait when asthma is not controlled. Moreover, the $\frac{322}{2}$ adopted rule-based model, with proper statistical validation, identified which specific $\frac{323}{223}$ values of the symptoms are associated to an impairment of cough-related quality of life. ³²⁴ The obtained results could support the physician in choosing the right 325 diagnostic/therapeutic plan. However, sensitivity and specificity of the developed model ³²⁶

> need to be verified in further prospective studies. Furthermore, future research in this 327 direction may investigate the adoption of other rule-based models than the LLM, as well $\frac{328}{228}$ as the usage of black-box algorithms with subsequent rule extraction. $\frac{329}{20}$

References

- 1. European Commission, Directorate-General for Communications Networks, Content and Technology, (2019) . Ethics guidelines for trustworthy AI – , Publications Office. https://data.europa.eu/doi/10.2759/346720
- 2. Bharati, S., Mondal, M. R. H., & Podder, P. (2023). A Review on Explainable Artificial Intelligence for Healthcare: Why, How, and When?. IEEE Transactions on Artificial Intelligence.
- 3. D. Saraswat et al., "Explainable AI for Healthcare 5.0: Opportunities and Challenges," in IEEE Access, vol. 10, pp. 84486-84517, 2022, doi: 10.1109/ACCESS.2022.3197671.
- 4. Hulsen, T. (2023). Explainable Artificial Intelligence (XAI): Concepts and Challenges in Healthcare. AI, 4(3), 652-666.
- 5. Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J 2020;55:1901136. 10.1183/13993003.01136-2019
- 6. Irwin RS, French CL,Chang AB, et al. Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report. Chest 2018;153:196-209. 10.1016/j.chest.2017.10.016
- 7. : Brew BK, Chiesa F, Lundholm C, Ortqvist A, Almqvist C (2019) A modern approach to identifying and characterizing child asthma and wheeze phenotypes based on clinical data. PLoS ONE 14(12): e0227091. https://doi.org/10.1371/journal.pone.0227091
- 8. Almqvist C, Ortqvist AK, Ullemar V, Lundholm C, Lichtenstein P, Magnusson ¨ PK. Cohort Profile: Swedish Twin Study on Prediction and Prevention of Asthma (STOPPA). Twin Res Hum Genet. 2015 Jun;18(3):273-80. doi: 10.1017/thg.2015.17. Epub 2015 Apr 22. PMID: 25900604.
- 9. Kang J, Seo WJ, Kang J, Park SH, Kang HK, Park HK, et al. (2023) Clinical phenotypes of chronic cough categorised by cluster analysis. PLoS ONE 18(3): e0283352. https://doi.org/ 10.1371/journal.pone.0283352
- 10. Koo HK, Jeong I, Kim JH, Kim SK, Shin JW, Park SY, Rhee CK, Choi EY, Moon JY, Kim YH, Lee H, Kang HS, Min KH, Kim JW, Kim JH, Lee SH, Yoo KH, Kim DK, Yoon HK, Kim DG, Kim HJ, Jung KS, Jang SH; Cough Study Group of the Korean Academy of Tuberculosis and Respiratory Diseases. Development and validation of the COugh Assessment Test (COAT). Respirology. 2019 Jun;24(6):551-557. doi: 10.1111/resp.13462. Epub 2019 Jan 25. PMID: 30681246.
- 11. Kwon JW, Moon JY, Kim SH, Song WJ, Kim MH, Kang MG, Lim KH, Lee SH, Lee SM, Lee JY, Kwon HS, Kim KM, Kim SH, Kim SH, Jeong JW, Kim CW, Cho SH, Lee BJ; Work Group for Chronic Cough, the Korean Academy of Asthma, Allergy and Clinical Immunology. Reliability and validity of a korean

> version of the leicester cough questionnaire. Allergy Asthma Immunol Res. 2015 May;7(3):230-3. doi: 10.4168/aair.2015.7.3.230. Epub 2014 Dec 18. PMID: 25749761; PMCID: PMC4397362.

- 12. Chen W, Schatz M, Zhou Y, Xie F, Bali V, Das A, Schelfhout J, Stern JA, Zeiger RS. Prediction of persistent chronic cough in patients with chronic cough using machine learning. ERJ Open Res. 2023 Mar 27;9(2):00471-2022. doi: 10.1183/23120541.00471-2022. PMID: 37009024; PMCID: PMC10052506.
- 13. Tong, Y., Messinger, A. I., & Luo, G. (2020). Testing the generalizability of an automated method for explaining machine learning predictions on asthma patients' asthma hospital visits to an academic healthcare system. IEEE Access, 8, 195971-195979.
- 14. Shim JS, Kim BK, Kim SH, Kwon JW, Ahn KM, Kang SY, Park HK, Park HW, Yang MS, Kim MH, Lee SM. A smartphone-based application for cough counting in patients with acute asthma exacerbation. J Thorac Dis. 2023 Jul 31;15(7):4053-4065. doi: 10.21037/jtd-22-1492.
- 15. Kaur S, Larsen E, Harper J, Purandare B, Uluer A, Hasdianda MA, Umale NA, Killeen J, Castillo E, Jariwala S. Development and Validation of a Respiratory-Responsive Vocal Biomarker-Based Tool for Generalizable Detection of Respiratory Impairment: Independent Case-Control Studies in Multiple Respiratory Conditions Including Asthma, Chronic Obstructive Pulmonary Disease, and COVID-19. J Med Internet Res. 2023 Apr 14;25:e44410. doi: 10.2196/44410.
- 16. Luo X, Gandhi P, Zhang Z, Shao W, Han Z, Chandrasekaran V, Turzhitsky V, Bali V, Roberts AR, Metzger M, Baker J, La Rosa C, Weaver J, Dexter P, Huang K. Applying interpretable deep learning models to identify chronic cough patients using EHR data. Comput Methods Programs Biomed. 2021 Oct;210:106395. doi: 10.1016/j.cmpb.2021.106395.
- 17. Tsang KCH, Pinnock H, Wilson AM, Shah SA. Application of Machine Learning Algorithms for Asthma Management with mHealth: A Clinical Review. J Asthma Allergy. 2022 Jun 29;15:855-873. doi: 10.2147/JAA.S285742. PMID: 35791395; PMCID: PMC9250768.
- 18. Baiardini, I.; Braido, F.; Fassio, O.; Tarantini, F.; Pasquali, M.; Tarchino, F.; Berlendis, A.; Canonica, G. A new tool to assess and monitor the burden of chronic cough on quality of life: Chronic Cough Impact Questionnaire. Allergy 2005, 60, 482–488.
- 19. Nathan, R.A.; Sorkness, C.A.; Kosinski, M.; Schatz, M.; Li, J.T.; Marcus, P.; Murray, J.J.; Pendergraft, T.B. Development of the asthma control test: a survey for assessing asthma control. Journal of Allergy and Clinical Immunology 2004, 113, 59–65
- 20. Muselli, M. Switching Neural Networks: A New Connectionist Model for Classification, 2005. https://doi.org/10.1007/11731177_4.
- 21. Parodi, S.; Manneschi, C.; Verda, D.; Ferrari, E.; Muselli, M. Logic Learning Machine and standard supervised methods for Hodgkins lymphoma prognosis using gene expression data and clinical variables. Health Informatics Journal 2016, 24. <https://doi.org/10.1177/1460458216655188>.

- 22. Cangelosi, D.; Blengio, F.; Versteeg, R.; Eggert, A.; Garaventa, A.; Gambini, C.; Conte, M.; Eva, A.; Muselli, M.; Varesio, L. Logic Learning Machine creates explicit and stable rules stratifying neuroblastoma patients. BMC bioinformatics 2013, 14, 1–20
- 23. Whatley, M. One-Way ANOVA and the Chi-Square Test of Independence. In Introduction to Quantitative Analysis for International Educators; Springer, 2022; pp. 57–74.
- 24. Vaccari, I.; Orani, V.; Paglialonga, A.; Cambiaso, E.; Mongelli, M. A generative adversarial network (GAN) technique for Internet of Medical Things data. Sensors 2021, 21, 3726.
- 25. Hicks, S.A.; Strümke, I.; Thambawita, V.; Hammou, M.; Riegler, M.A.; Halvorsen, P.; Parasa, S. On evaluation metrics for medical applications of artificial intelligence. Scientific Reports 2022, 12, 1–9.
- 26. <https://www.rulex.ai>

Fig. 1

Fig. 3

It is made available under a CC-BY 4.0 International license. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.04.23296540;](https://doi.org/10.1101/2023.10.04.23296540) this version posted October 5, 2023. The copyright holder for this preprint
(<mark>which was not certified by peer review)</mark> is the author/funder, who has grante

Fig. 4

Fig. 5A

Fig. 5B

Fig. 5C